Peptide Molecular Weight and CAS Numbers

What do peptide molecular weight, sequence and CAS numbers identify?

Peptide records usually include several identifiers because no single field describes a molecule completely. Molecular weight, amino acid sequence and CAS Registry Number each answer a different question about identity, composition and reference matching.

For researchers and laboratory professionals, these identifiers are most useful when they are interpreted together. A sequence may describe the amino acid order, a molecular weight may reflect a specific chemical form, and a CAS number may correspond to a registered substance, salt, complex or modification.

This article focuses on chemical and documentation concepts, not biological activity or human use. Where scientific evidence is mentioned, the evidence level is stated so that chemical identification is not confused with biomedical conclusions.

Research Notice
This article discusses published scientific research. It is provided for educational purposes only and does not provide medical advice, dosing, administration or human-use instructions.

1. Peptide molecular weight in research records

Peptide molecular weight is the calculated or measured mass of a peptide molecule, commonly reported in daltons or grams per mole. This is a chemical descriptor based on atomic composition, not a controlled human trial, animal study, observational human study or in vitro efficacy finding.

For an unmodified linear peptide with free amino and carboxyl termini, the molecular weight is calculated from the sum of amino acid residue masses plus the elements of water. The water term is included because peptide-bond formation removes water between residues, while the complete chain retains terminal groups.

Researchers often distinguish average molecular weight from monoisotopic mass. Average molecular weight uses naturally occurring isotope abundances, while monoisotopic mass uses the most abundant isotope of each element; this distinction is an analytical chemistry convention rather than biomedical evidence.

Mass spectrometry workflows may report observed mass-to-charge ratios, deconvoluted molecular masses or isotope envelopes. These measurements provide analytical evidence about a sample under defined instrument conditions, but they do not establish purity, biological effect, safety or equivalence to another material.

Several factors can change a peptide’s reported molecular weight. These include terminal acetylation or amidation, disulfide bond formation, phosphorylation, glycosylation, lipidation, metal coordination, salt form, counterion content and hydration state.

For example, a peptide listed as a trifluoroacetate salt can have a different formula weight from the same peptide listed as an acetate salt or free base. That difference is a matter of chemical form and should not be interpreted as a difference in clinical evidence.

2. Amino acid sequence notation and directionality

A peptide sequence records the order of amino acid residues, conventionally written from the N-terminus to the C-terminus. This convention is defined in biochemical nomenclature sources such as IUPAC-IUBMB recommendations and is not a biomedical efficacy claim.

Sequences may be written using one-letter codes, such as GHK, or three-letter codes, such as Gly-His-Lys. One-letter notation is compact, while three-letter notation can reduce ambiguity when non-standard residues, stereochemistry or modifications are present.

Standard proteinogenic amino acids are usually assumed to be in the L-configuration unless otherwise stated. D-amino acids, beta-amino acids, N-methylated residues and other non-standard units should be explicitly described because they can alter molecular formula, conformation and analytical behaviour.

Sequence alone may be insufficient for complete identification. Two materials can share the same residue order but differ by terminal groups, salt form, isotopic labelling, cyclization, disulfide connectivity or coordinated metal ions.

Cyclic peptides require additional notation because the sequence does not always show which atoms form the ring. Disulfide-containing peptides also need connectivity information, particularly when more than two cysteine residues are present.

For database searches, researchers may compare the stated sequence with entries in resources such as UniProt, PubChem, ChemSpider, Protein Data Bank records and supplier documentation. Database agreement is useful for record-keeping, but it is not a substitute for analytical verification of a specific sample.

3. CAS Registry Numbers and what they do not prove

A CAS Registry Number is a numeric identifier assigned by the Chemical Abstracts Service to a substance in its registry. It is a reference tool for chemical indexing and literature retrieval, not a statement of regulatory approval, product quality, purity, safety or biological effect.

CAS numbers are useful because common names, abbreviations and synonyms can vary widely. A single peptide may appear under a systematic name, a short sequence name, a research code, a trade-related term or a modified chemical name.

However, CAS numbers must be interpreted carefully. Different stereoisomers, salts, solvates, complexes, protected intermediates or labelled forms may have different CAS numbers, even when their names appear similar in informal discussion.

The reverse can also create confusion: a broad registry entry may be cited in secondary sources without enough detail to confirm the exact material form under discussion. Researchers should compare the CAS number with formula, sequence, termini, salt form and any modifications.

A CAS number does not confirm that a product conforms to a pharmacopeial monograph or that it has any authorised clinical use. Those are separate regulatory and quality questions that require appropriate documentation from recognized authorities or validated analytical testing.

4. Reconciling formula, sequence and analytical data

Good peptide documentation usually begins by aligning the name, sequence, molecular formula and molecular weight. If one field does not match the others, the discrepancy may reflect a modification, salt, counterion, hydration state, calculation basis or documentation error.

A common first check is whether the reported mass corresponds to the neutral peptide, the salt form or a modified derivative. For example, amidation at the C-terminus changes the elemental composition compared with a free carboxyl terminus.

Another check is whether the reported molecular weight is average or monoisotopic. Comparing a monoisotopic mass from mass spectrometry with an average molecular weight from a catalogue can create an apparent mismatch even when both values are internally correct.

Analytical methods answer different questions. High-performance liquid chromatography may separate components under a specified method, mass spectrometry may support identity by mass, and nuclear magnetic resonance may provide structural information for suitable molecules.

These techniques provide laboratory evidence about chemical characteristics. They should not be described as controlled human trial evidence, observational human evidence, animal evidence or proof of any human outcome.

5. Common documentation pitfalls for peptides

One frequent pitfall is treating a short peptide abbreviation as a complete identity. Abbreviations may omit terminal modifications, salt form, stereochemistry, metal complexation or disulfide pairing.

Another pitfall is comparing molecular weights from different sources without checking the calculation assumptions. A value calculated for a free peptide may not match a value reported for a salt, complex or lyophilized material containing residual water.

Researchers should also be cautious when copying CAS numbers from secondary websites. A CAS number may refer to a related parent compound rather than the exact modified peptide or salt under review.

For record-keeping, it is often helpful to document the source of each identifier. A laboratory notebook or materials management system can separately record sequence, formula, molecular weight type, CAS number, lot-specific analytical files and date of review.

What Does the Research Show?

The relevant literature on peptide identifiers is mainly based on chemical nomenclature standards, analytical chemistry methods and database indexing practices. These are not human therapeutic studies and should not be interpreted as evidence that any peptide product has a medical effect.

• In vitro evidence: Analytical chemistry studies can use techniques such as liquid chromatography and mass spectrometry to characterize peptide mass, impurities or degradation products under laboratory conditions.
• Animal evidence: Animal studies may report a peptide sequence or molecular weight as part of experimental methods, but those identifiers do not themselves establish translation to humans.
• Observational human evidence: Human observational papers may identify endogenous or administered peptides in biological samples, but identifier fields are documentation tools, not proof of causation or benefit.
• Controlled human trial evidence: Clinical trials involving peptide-based drugs may report molecular identity and formulation details, but results apply to the studied investigational or authorised product under trial conditions.
• Established authorised clinical use: Some peptide medicines have authorised clinical uses in specific jurisdictions, but that status is product-specific and cannot be transferred to unrelated research materials or catalogue listings.

In practice, molecular weight, sequence and CAS number are best viewed as complementary identifiers. They help researchers compare records, evaluate documentation and plan analytical verification, while leaving biological interpretation to appropriately designed studies.

Related Research Product

For an example of a peptide entry where researchers may compare sequence, molecular-weight notation and registry information, Lux Peptides lists GHK-Cu.

Educational Disclaimer
This article is provided for scientific and educational purposes only. It does not describe or imply the safety, effectiveness or intended use of any Lux Peptides product.

Nothing in this article is intended to diagnose, treat, cure or prevent disease or provide instructions for human use.

Lux Peptides

See Full Bio